RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by National Cancer Center / Cancer Hospital, CAMS; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)National Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07200947, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed diagnosis of Stage IIIB-IV lung cancer that is not amenable to curative surgery or radiotherapy.

    Inclusion criterion 4

    Tumor demonstrates loss of BRG1 protein (encoded by the SMARCA4 gene) as confirmed by immunohistochemistry (IHC).

    Inclusion criterion 5

  3. History of another active malignancy within the past 2 years (with specific exceptions for certain early-stage cancers).

    Exclusion criterion 14

  4. Recurrence within 6 months after completing prior adjuvant therapy (if applicable).

    Exclusion criterion 4

    Treatment with any investigational drug within 4 weeks prior to the first dose of study treatment.

    Exclusion criterion 12

    Use of Chinese herbal medicines with anti-tumor activity within 2 weeks prior to study treatment initiation.

    Exclusion criterion 13

  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    Inclusion criterion 7

  6. At least one measurable lesion as defined by RECIST v1.1.

    Inclusion criterion 9

  7. Known HIV infection, active Hepatitis B (HBsAg positive with HBV-DNA > 10\^3 copies/mL), or active Hepatitis C (HCV antibody positive with detectable HCV-RNA).

    Exclusion criterion 10

  8. Pregnancy or lactation in female participants.

    Exclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07200947, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

Participants must meet all of the following criteria to be eligible for the study:

  • Voluntary participation and provision of signed written informed consent.
  • Age ≥ 18 years.
  • Life expectancy ≥ 3 months.
  • Histologically or cytologically confirmed diagnosis of Stage IIIB-IV lung cancer that is not amenable to curative surgery or radiotherapy.
  • Tumor demonstrates loss of BRG1 protein (encoded by the SMARCA4 gene) as confirmed by immunohistochemistry (IHC).
  • No prior systemic anti-cancer therapy for advanced disease.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Willingness to provide archived or fresh tumor tissue samples from primary or metastatic lesions. If unavailable, enrollment may be permitted following investigator assessment.
  • At least one measurable lesion as defined by RECIST v1.1.
  • Adequate organ function within the screening period, as evidenced by:

10.1 Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L 10.2 Platelet count ≥ 100 × 10\^9/L 10.3 Hemoglobin ≥ 90 g/L (without transfusion within 14 days) 10.4 Serum creatinine ≤ 1 × ULN OR Creatinine clearance > 50 mL/min (calculated by Cockcroft-Gault formula) 10.5 AST and ALT ≤ 2.5 × ULN (≤ 5 × ULN for patients with liver metastases) 10.6 Total bilirubin ≤ 1.5 × ULN (except for participants with Gilbert's syndrome) 10.7 TSH, FT3, and FT4 within normal limits (±10%)

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded from the study:

  • Pathological diagnosis containing a small cell component.
  • Symptomatic brain metastases.
  • Leptomeningeal metastases.
  • Recurrence within 6 months after completing prior adjuvant therapy (if applicable).
  • Active, known, or suspected autoimmune disease (with specific exceptions, e.g., vitiligo, type I diabetes, hypothyroidism managed with hormone replacement only).
  • Active tuberculosis (TB) infection or history of active TB within the past year.
  • Comorbidities requiring immunosuppressive medications, including systemic corticosteroids at immunosuppressive doses.
  • Pregnancy or lactation in female participants.
  • Symptomatic interstitial lung disease that could interfere with the detection or management of suspected drug-related pulmonary toxicity.
  • Known HIV infection, active Hepatitis B (HBsAg positive with HBV-DNA > 10\^3 copies/mL), or active Hepatitis C (HCV antibody positive with detectable HCV-RNA).
  • Significant history of neurological or psychiatric disorders.
  • Treatment with any investigational drug within 4 weeks prior to the first dose of study treatment.
  • Use of Chinese herbal medicines with anti-tumor activity within 2 weeks prior to study treatment initiation.
  • History of another active malignancy within the past 2 years (with specific exceptions for certain early-stage cancers).
  • Significant cardiovascular or cerebrovascular disease history.
  • Uncontrolled thrombotic events within 6 months prior to screening.
  • Administration of a live vaccine within 28 days prior to the first study dose.
  • Major surgery or significant trauma within 4 weeks prior to the first study dose.
  • Conditions that may impair oral drug absorption.
  • Uncontrolled active infection requiring systemic therapy.
  • Known hypersensitivity to any of the study drug components.
  • Any other condition that, in the investigator's judgment, would make the participant unsuitable for participation in the study.

Quoted from ClinicalTrials.gov, NCT07200947, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07200947, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07200947